The 9th edition of India Pharma 2026 signals a strategic shift in India’s pharmaceutical sector—from large-scale generic production to high-value biopharmaceutical innovation.
While India supplies 20% of global generics and 70% of vaccines, policy focus is now turning toward biosimilars and specialty medicines, which offer higher value and global demand.
A key announcement was the ₹10,000 crore Biopharma Shakti Initiative, designed to strengthen research, accelerate drug discovery, and improve domestic manufacturing capabilities. The programme builds on existing schemes like PRIP (Promotion of Research in Pharmaceuticals) and PLI (Production Linked Incentive), to bridge gaps between industry, academia, and innovation ecosystems.
The shift also includes greater use of Artificial Intelligence (AI) in drug discovery and expansion of bulk drug parks to secure supply chains, positioning India for a larger role in the global pharmaceutical value chain.
Key Growth & Strategy Pillars
Biopharma Shakti Initiative: A ₹10,000 crore fund specifically for biopharmaceutical innovation and research.
Market Opportunity: The global biosimilars market is expected to hit $75 billion by 2030, a segment India is now aggressively targeting.
Manufacturing Strength: India hosts over 10,500 manufacturing units and has the highest number of USFDA-compliant plants outside the US.
Research Focus: The PRIP scheme will prioritize deep-tech areas, including specialty medicines and medical technology.
Digital Integration: A new emphasis on using Artificial Intelligence (AI) to cut down the time and cost of discovering new life-saving drugs.
Human Capital: Strengthening the role of NIPERs and IITs to create a workforce capable of handling advanced biopharma research.
What are "Biosimilars"?
Biosimilars are medical products that are almost identical versions of original "biological" medicines (drugs made from living organisms). They work differently than standard generic drugs; while a generic is a chemical copy, a biosimilar is a highly complex biological "match" that is just as safe and effective as the original.
They are significant because biologics currently make up 87% of the global market's value but are often extremely expensive. By mastering biosimilars, Indian companies can provide high-end treatments for cancer and autoimmune diseases at a fraction of the current cost, just as they did for traditional medicines.
Policy Relevance
Shifts the Sector to Higher Value Margins: Moving from generics to innovative drugs helps Indian companies capture more of the $1.5 trillion global pharma market value.
Enhances National Health Security: Developing domestic capabilities in biologics ensures that India isn't dependent on expensive imports for next-generation treatments.
Attracts Global R&D Investment: The ₹10,000 crore Biopharma Shakti fund and streamlined regulatory approvals make India a more attractive destination for global clinical trials and research partnerships.
Maintains Global Vaccine Leadership: Strengthening the biopharma ecosystem ensures India remains the primary supplier of vaccines for global health emergencies.
Relevant Question for Policy Stakeholders: How can the industry-academia gap be bridged to ensure that research done in NIPERs and IITs is directly aligned with the commercial needs of large Indian pharma companies?
Follow the Full News Here: 9th India Pharma Highlights Policy Push